A Phase 1/2A Single Center Trial of Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using the Drug LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)

Trial Profile

A Phase 1/2A Single Center Trial of Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using the Drug LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs EB 101 (Primary)
  • Indications Epidermolysis bullosa
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 29 Aug 2017 Results published in an Abeona Therapeutics Media Release.
    • 29 Aug 2017 According to an Abeona Therapeutics media release, based on the data from this study, the US FDA granted EB 101 Breakthrough therapy designation for use in patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB).
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top